Case Studies
4D has conducted a number of projects with Universities, NHS Trusts and other key players in the field of Translational Medicine. The case studies below are a sample of the type of project work 4D-Biomedical has historically been involved with.
Kings College London: Commercialisation of the CRIS patient database for the Institute of Psychiatry
Client: National Institute for Health Research Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and King's College London Institute of Psychiatry
Project: Use of a database of anonymised patient information and informatics system to facilitate research for patient benefit with external partners.
Deliverables: Utility assessment, industry interviews and development options appraisal. Recommended a development strategy including a list of key potential industry collaborators.
Institute of Digestive Health - University College London
Client: UCL Partners, Royal Free Hospital NHS trust and University College Hospital NHS trust.
Project: Re-organisation of gastro-hepatology in North London into a 'Mayo Clinic' style single digestive health institute, to translate research and new models of care into the community and strengthen links with general practice, whilst harnessing the unique potential of a 2 million patient catchment for research.
Deliverables: Audit of academic, clinical and industrial potential. Strategic planning of governance and leadership.
Outcome: The strategy suggested by 4D-Biomedical was approved by UCLH and is now being implemented in a new Institute.
Institute of Cardiovascular Science - University College London
Client: UCL Partners, Great Ormond Street Hospital and University College Hospital NHS trust.
Project: Assess, model, plan and establish the first therapeutic Programme for UCL Partners in cardiovascular science, establishing a new Institute drawing on the expertise across UCL Partner organisations.
Deliverables: Clinical and research audit, analysis of industry needs. Developed a strategy for the exploitation of intellectual property. Provided a 10 year business plan and provided hands-on support for the formation of the Institute.
"The 4D Biomedical team brought great professionalism to our project. Their advice was invaluable".
Professor Andrew Copp MBBS DPhil FRCPath FMedSci
Director, UCL Institute of Child Health
Non-Executive Director, Great Ormond Street Hospital.
Leeds Institute of Genetics and Therapeutics
Client: Leeds Institute of Genetics, Helath and Therapeutics
Project: Following an introduction by one of the UK's leading research charities, we were approached and engaged to prepare a translational research strategy and IPR exploitation model for a major NHS Trust and University in a major urban conurbation.
Deliverables: Building on the existing facilities and research in place, we developed a model for accelerating the integration of clinical and academic science.
Outcome: We helped structure and develop a major new Joint Venture between the Trust and University.
‘The team at 4D have the expertise and understanding to skilfully cover the gap that currently exists between academia and commercialisation. Approachable, informed and able to perform swift analysis of problems and potential solutions relevant to this difficult area. Tremendously valuable partners to help guide you through the commercialisation processes’
Peter J Grant
Professor of Medicine
Honorary Consultant Physician
Head, Division of Cardiovascular & Diabetes Research
The LIGHT Laboratories, Clarendon Way
GENESERVICE
Client: Geneservice
Project: 4D was engaged by the management of Geneservice to help with the planning and preparation of their successful acquisition in 2007.
Deliverables: We provided a combination of market intelligence and analysis on key trends in the pharmacogenomics sector and their potential acquirors, and hands-on support with the preparation of the business case.
Outcome: Geneservice were aquired in 2007
"The 4D team provided invaluable, practical transaction support in our successful bid to be acquired. Their combination of industry and finance expertise, hands-on approach and understanding of how deals work was invaluable. "
Tom Weaver
Former CEO, Geneservice
Translational medicine collaboration
In summer 2005 we were retained by Scottish Enterprise to conduct research into the market for biomarker collaborations around the world, and to advise on the most appropriate commercialisation model for a Scottish consortium. Following that project, we were retained to advise the consortium of NHS Trusts, four universities and Scottish Enterprise on the transaction with Wyeth Pharmaceuticals including:
- Developing a business model for the collaboration, including novel mechanisms for licensing of biomarker IP
- Tracking comparator deals - both biomarker licensing and public health collaborations - around the world
- Preparing robust intellectual property licensing revenue forecasts
- Supporting the negotiation of IP and Collaboration Agreement
- Preparing financial cost and revenue models
Client: Scottish Enterprise, 4 NHS trusts and Universities, including, Universities of Edinburgh, Glasgow, Dundee and Aberdeen.
Project: Business plan to establish support for the world's first national Translational Medicine collaboration with the pharmaceutical industry.
Deliverables: Business case and 10 year business plan, intellectual property licensing model and forecasts, operating model for collaboration management and liaison between Wyeth (now Pfizer), NHS, academics and government.
Outcome: Collaboration signed in April 2006 with $50m investment from Wyeth (now Pfizer) in programmes across 5 therapeutic areas. Wyeth was awarded a 'best investment in Europe' title at the La Baule world investment conference in 2006 for its role in Translational Medicines Research Collaboration.
Press Release: Translational Medicine Research Collaboration is awarded “Best Investment in Europe”
Wyeth Pharmaceuticals has been awarded one of three 'Best Investment in Europe' titles at the La Baule World Investment Conference for its role in creating the world's first Translational Medicine Research Collaboration (TMRC) in Scotland in 2006.
The 4D Biomedical team advised Scottish Enterprise on the collaboration.
Wyeth Pharmaceuticals, with headquarters in Collegeville, Pennsylvania, plans to invest an estimated £33m in the collaboration in its first five years, with an option to extend for a further five years. Scottish Enterprise will invest up to £17.5m.
The £50 million collaboration comprises four of Scotland's leading universities (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceuticals, Scottish Enterprise and NHS Scotland Grampian, Greater Glasgow, Lothian and Tayside, and will provide new impetus for Scotland to lead the world in the development of personalised medicine, bringing new treatments to patients suffering from a range of serious illnesses.
TMRC has already invested almost £8 million of funding to support 28 new research projects covering a wide range of therapeutic areas including cardiovascular and metabolic disease, the central nervous system, oncology, inflammation, and women's health.
As a result, over 40 new jobs have already been created with a further 50 projected for the project’s Core Laboratory in Dundee.
Contact us to find out what we can do for your business.